VERV - Verve Therapeutics, Inc. Stock Price, Fair Value and News

$11.13

Market Closed as of 25 Jul 2025, 04:00 pm ET

VERV Stock Valuation Analysis

Valuation

Max Portfolio %

VERV Price Action

VERV RSI Chart

VERV Stock Valuation Analysis

Valuation

Max Portfolio %

VERV Valuation

VERV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VERV Fundamentals

VERV Revenue

VERV Earnings

VERV Profitability

VERV Investor Care

Revenue & Growth

How Verve Therapeutics, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2025	59.6M	-	-	-
2024	16.0M	20.6M	24.4M	32.3M
2023	4.4M	6.8M	9.3M	11.8M
2022	-	-	-	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Sekar Kathiresan M.D.
WEBSITE	vervetx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	204